Zogenix (NASDAQ:ZGNX) Earns Daily Media Sentiment Rating of 0.02

Press coverage about Zogenix (NASDAQ:ZGNX) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zogenix earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.3015472683461 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

A number of research analysts have recently issued reports on the stock. ValuEngine raised shares of Zogenix from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub raised shares of Zogenix from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 1st. Leerink Swann lifted their price objective on shares of Zogenix from $50.00 to $54.00 and gave the stock an “outperform” rating in a research report on Friday, February 23rd. Zacks Investment Research raised shares of Zogenix from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday, March 15th. Finally, Mizuho reissued a “buy” rating and issued a $51.00 price target on shares of Zogenix in a research report on Thursday, May 10th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $53.20.



Shares of Zogenix opened at $44.80 on Friday, MarketBeat Ratings reports. Zogenix has a 12 month low of $10.05 and a 12 month high of $45.85. The company has a market cap of $1.49 billion, a P/E ratio of -11.14 and a beta of 1.76.

Zogenix (NASDAQ:ZGNX) last released its quarterly earnings results on Wednesday, May 9th. The company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.13). During the same period last year, the firm earned ($0.86) EPS. equities analysts forecast that Zogenix will post -3.89 EPS for the current year.

In other Zogenix news, EVP Gail M. Farfel sold 5,118 shares of the company’s stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $230,310.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply